Business
Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
RAHWAY, N.J., October 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from November 7–10. Data presented at AHA highlight Merck’s continued dedication to advancing research across hypercholesterolemia and pulmonary arterial hypertension (PAH) to help address the global burd
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/b0bbe0f549c4fc0286d9bcec999412a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7dSzJ_dZaV8lyD2sjcmHPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b0bbe0f549c4fc0286d9bcec999412a1","width":480,"height":217}},"lazy":false},{"type":"text","content":"Results from the Phase 3 CORALreef Lipids and HeFH trials of investigational oral PCSK9 inhibitor enlicitide decanoate will be presented for the first time","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"Presentations across hypercholesterolemia and pulmonary arterial hypertension (PAH) underscore Merck’s continued commitment to research with the goal of helping address the cardiovascular (CV) epidemic and significant burden of cardio-pulmonary diseases on public health","length":270,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., October 23, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from November 7–10. Data presented at AHA highlight Merck’s continued dedication to advancing research across hypercholesterolemia and pulmonary arterial hypertension (PAH) to help address the global burden of cardio-pulmonary diseases.","length":549,"tagName":"p"},{"type":"text","content":"Key data being presented:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First presentation of detailed findings from the pivotal Phase 3 CORALreef Lipids trial, the largest study of enlicitide decanoate reported to date, evaluating the safety and efficacy of enlicitide, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in adults with hypercholesterolemia and a history of a major atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first event","length":452,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First presentation of detailed findings from the Phas...